2023 World Conference on Lung Cancer (Posters)-P2.07. Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry

Pdf Summary

The study presented at WCLC 2023 focused on the use of immune checkpoint blockers (ICBs) in lung cancer patients who have undergone solid organ transplantation (SOT). Due to the risk of allograft rejection and the potential interference of immunosuppressive drugs, these patients have typically been excluded from clinical trials involving ICBs. The objective of the study was to collect real-world data on the efficacy and safety of ICBs in SOT patients with advanced lung cancer.<br /><br />The study was part of the INNOVATED multicenter registry, which retrospectively analyzed data from patients with SOT and advanced solid cancer. For this report, data from 11 patients with stage IV lung cancer who had previously undergone kidney transplantation were extracted. The median age of the patients was 64.8 years, with 27% being females and 18% never smokers. The most common histological subtypes were squamous cell carcinoma and adenocarcinoma. The main metastatic sites were the liver, bone, and lung.<br /><br />The study found that ICB therapy resulted in an overall response rate (ORR) of 45.5% and a disease control rate (DCR) of 54.5% in this group of patients. The median progression-free survival (PFS) and overall survival (OS) were 4.0 and 4.6 months, respectively, with a 6-month PFS and OS of 32.7% and 42.2%. One case of organ rejection (9.1%) and one grade 3 immune-related adverse event (colitis) were reported.<br /><br />Based on these findings, the study suggests that ICBs could be a viable treatment option for patients with metastatic lung cancer after kidney transplantation, particularly when other therapeutic alternatives are limited. However, close collaboration with transplant experts, careful modification of immunosuppression, and close monitoring of this vulnerable patient population are recommended to minimize the risk of allograft rejection.<br /><br />In summary, this study provides real-world data on the use of ICBs in lung cancer patients who have undergone solid organ transplantation, demonstrating the potential efficacy of this treatment option.

Asset Subtitle

Jordi Remon Masip

Meta Tag

Speaker Jordi Remon Masip

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immune checkpoint blockers

lung cancer

solid organ transplantation

allograft rejection

immunosuppressive drugs

clinical trials

efficacy and safety

INNOVATED multicenter registry

stage IV lung cancer

kidney transplantation